Schroder Investment Management Group Raises Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Schroder Investment Management Group raised its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 111.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 156,874 shares of the company's stock after acquiring an additional 82,601 shares during the quarter. Schroder Investment Management Group owned 0.30% of Janux Therapeutics worth $8,236,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Rhumbline Advisers lifted its stake in shares of Janux Therapeutics by 1.6% in the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock valued at $2,043,000 after purchasing an additional 599 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Janux Therapeutics by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock valued at $596,000 after acquiring an additional 1,095 shares during the period. Virtu Financial LLC boosted its stake in shares of Janux Therapeutics by 17.5% during the 4th quarter. Virtu Financial LLC now owns 8,769 shares of the company's stock worth $469,000 after acquiring an additional 1,306 shares in the last quarter. Avanza Fonder AB acquired a new stake in shares of Janux Therapeutics in the 4th quarter worth approximately $139,000. Finally, Zacks Investment Management increased its stake in Janux Therapeutics by 8.7% in the 3rd quarter. Zacks Investment Management now owns 42,133 shares of the company's stock valued at $1,914,000 after purchasing an additional 3,360 shares in the last quarter. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling at Janux Therapeutics

In other news, CEO David Alan Campbell sold 5,000 shares of the firm's stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total value of $300,000.00. Following the transaction, the chief executive officer now directly owns 293,054 shares in the company, valued at $17,583,240. This trade represents a 1.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. acquired 341,742 shares of Janux Therapeutics stock in a transaction dated Wednesday, March 5th. The stock was purchased at an average cost of $30.64 per share, for a total transaction of $10,470,974.88. Following the completion of the purchase, the director now directly owns 9,658,988 shares in the company, valued at approximately $295,951,392.32. This represents a 3.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 11,668 shares of company stock worth $548,183 in the last quarter. 29.40% of the stock is owned by insiders.

Analyst Ratings Changes

JANX has been the topic of a number of research analyst reports. Lifesci Capital upgraded Janux Therapeutics to a "strong-buy" rating in a research report on Friday, December 27th. Scotiabank decreased their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 28th. Cantor Fitzgerald reissued an "overweight" rating and issued a $200.00 price objective on shares of Janux Therapeutics in a research note on Wednesday, December 11th. Wedbush restated an "outperform" rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Finally, HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $92.44.

Janux Therapeutics Stock Down 5.4 %

Shares of JANX stock traded down $1.39 during mid-day trading on Monday, hitting $24.38. 1,871,015 shares of the company's stock were exchanged, compared to its average volume of 856,610. The stock has a 50-day simple moving average of $34.09 and a two-hundred day simple moving average of $45.24. Janux Therapeutics, Inc. has a fifty-two week low of $23.40 and a fifty-two week high of $71.71. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -20.84 and a beta of 3.27.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.